We are live on ! Find out more

Pharming Group

PHAR

Market cap $871M

12.29 USD

-0.01

0.08%

At close Updated Nov 6, 4:00 PM EST

1 day

-0.08%

5 days

-3.61%

1 month

26.96%

3 months

13.27%

6 months

-25.06%

Year to date

-28.3%

1 year

-16.39%

5 years

33.3%

10 years

-26.41%

About: Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Employees: 409

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 7.1%

Neutral 92.9%

Negative 0%

MHRA approves Pharming's Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.

MHRA approves Pharming's Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. Approval extends existing U.K. indication.

MHRA approves Pharming's Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.

Pharming Group N.V. (PHAR) Q3 2026 Earnings Call Transcript

Pharming Group N.V. ( PHAR ) Q3 2026 Earnings Call October 27, 2026 8:30 AM EDT Company Participants Kenneth Lynard - CFO & Co-Chief Executive Officer Leverne Marsh - Co-CEO & Chief Commercial Officer Anurag Relan - Chief Medical Officer Conference Call Participants Benjamin Jackson - Jefferies LLC, Research Division Sushila Hernandez - Kempen & Co. N.V.

Pharming Group N.V. (PHAR) Q3 2026 Earnings Call Transcript

Pharming Group Q3 Earnings Call Highlights

Pharming Group NASDAQ: PHAR reported third-quarter revenue growth of 21% to $117.6 million, supported by higher sales of its RUCONEST hereditary angioedema treatment and Joenja therapy for activated phosphoinositide 3-kinase delta syndrome, or APDS.

Pharming Group Q3 Earnings Call Highlights

Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November

Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectations RUCONEST® revenue increased by 14% to US$93.8 million, compared to third quarter 2025, reflecting demand stabilization and seasonal inventory increase Joenja® (leniolisib) revenue increased by 58% to US$23.8 million, compared to third quarter 2025, reflecting strong U.S. and international demand Tightened 2026 total revenue guidance to US$380 million - US$390 million from prior US$375 million - US$395 million Operating profit increased by 89% to US$29.9 million, compared to third quarter 2025 Generated US$32.4 million in cash flow from operations in the quarter and US$24.7 million year to date, increasing cash position to US$190.9 million Strong progress on Joenja expansion including U.S. pediatric label and launches in Germany and Japan Announced positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation and Phase II topline data in broader CVID patient population expected in November 2026 Pharming to host a conference call today at 13:30 CET (8:30 am EDT) Leiden, the Netherlands, October 27, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, presents its preliminary (unaudited) financial report for the three months ended September 30, 2026.

Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November

Pharming Group announces third quarter 2026 revenues above market expectations

Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025 Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third quarter 2025 Tightened 2026 total revenue guidance to US$380 million - US$390 million from prior US$375 million - US$395 million Full third quarter financial results and business update brought forward to October 27, 2026; conference call and webcast for analysts and investors to follow at 13:30 CET/08:30 EDT Leiden, the Netherlands, October 22, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announces preliminary, unaudited revenue and select financial information for the three months ended September 30, 2026.

Pharming Group announces third quarter 2026 revenues above market expectations

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulation Leniolisib was well-tolerated, with benefits observed across multiple measures of immune dysregulation, including improvement in lymphoproliferation and positive trends in lung and liver disease markers All participants who completed the study elected to continue receiving treatment in a long-term extension study Leiden, the Netherlands, October 14, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today presented positive topline data from its Phase II trial of leniolisib in genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation linked to altered PI3Kδ signaling. The data, accepted as a late-breaking abstract, were presented as a poster at the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID), taking place October 14-17, 2026, in Maastricht, the Netherlands.

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Pharming Group: Viable Contrarian Buy If Ruconest Stabilizes

RUCONEST is Pharming Group's main revenue source today. This asset has already shown a sequential sales rebound that makes me more optimistic. However, RUCONEST still has oral competition that could make stabilizing that revenue bleed more challenging. Still, my bull case assumes RUCONEST's issues are manageable. If so, that could buy time for Joenja to grow and improve the business mix.

Pharming Group: Viable Contrarian Buy If Ruconest Stabilizes

Pharming announces CEO transition

Leiden, the Netherlands, September 29, 2026 : Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Mr. Chouraqui will step down as Chief Executive Officer and Executive Director, with immediate effect.

Pharming announces CEO transition

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

If approved, J oenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more Decision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least 27 kg PDUFA target action date of January 30, 2027 Leiden, the Netherlands, September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for lower doses of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, for children aged 4 years and older who weigh between 13 kg and 27 kg with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. The application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2027.

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report topline results from a Phase II trial of leniolisib in CVID in Q4 2026 Leiden, the Netherlands, September 22, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that a late-breaking abstract highlighting positive topline data from its Phase II trial with leniolisib in genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kd signaling has been accepted at the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID), which will take place October 14-17, in the Netherlands. This trial is a single-arm, open-label, intra-patient dose-escalation Phase II study of leniolisib evaluating safety and tolerability, pharmacokinetic, pharmacodynamic and efficacy measures in 13 subjects with genetically defined PIDs.

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

See News Rankings

Price charts implemented using Lightweight Charts™